Abstract
There are limited data on real-world effectiveness of the specific factor Xa (FXa) inhibitor reversal agent andexanet alfa (AA) in comparison with 4-factor prothrombin complex concentrates (4F-PCC). We compared in-hospital mortality in patients hospitalized with oral FXa inhibitor- or enoxaparin- related intracranial hemorrhage (ICH) or gastrointestinal (GI) bleeds who were treated with AA or 4F-PCC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
